Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6.
Since the discovery of the virus in 1994, the rapid pace with which Karposi's sarcoma-associated herpesvirus (KSHV) research has progressed has quickly led to a broad understanding of the structure of the virus and its biology and pathology in humans. Molecular piracy of potentially useful cellular genes has emerged as a characteristic feature of this virus. The viral homolog of human IL-6, vIL-6 is an example in kind. Studies in vitro and in vivo have shown that vIL-6 can stimulate the growth of KSHV-infected primary infusion lymphoma (PEL) cells, can promote hematopoiesis, and act as an angiogenic factor through the induction of vascular endothelial growth factor (VEGF). It is not difficult to envision how vIL-6, through these properties and perhaps others yet to be identified, can contribute to KSHV survival and spread in the human population.
Aoki
Y
Y
Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Jones
K D
KD
Tosato
G
G
D006410:Hematopoiesis / Q000187:drug effects; D006566:Herpesviridae Infections / Q000150:complications / Q000503:physiopathology; D019288:Herpesvirus 8, Human / Q000737:chemistry*; D006801:Humans; D015850:Interleukin-6 / Q000502:physiology*; D012196:Review Literature as Topic; D012514:Sarcoma, Kaposi / Q000097:blood* / Q000503:physiopathology / Q000821:virology; D014764:Viral Proteins / Q000502:physiology
D015850:Interleukin-6; D014764:Viral Proteins